[
  {
    "ts": "2026-02-27T09:14:19+00:00",
    "headline": "A Look At Viatris (VTRS) Valuation After Earnings Beat And 2026 Guidance Update",
    "summary": "Viatris (VTRS) shares reacted to a busy update cycle after the company reported a fourth quarter revenue and adjusted earnings beat, along with fresh 2026 guidance, a cost saving plan, and refreshed capital return commitments. See our latest analysis for Viatris. Even after a 5.16% one day share price decline and a 4.57% seven day share price pullback around the earnings release and guidance, Viatris is still up 16.23% on a 30 day share price basis and 42.66% over 90 days. Its 1 year total...",
    "url": "https://finance.yahoo.com/news/look-viatris-vtrs-valuation-earnings-091419452.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "7bc505e5-f1a2-38c5-9af3-b5a76e7d247d",
      "content": {
        "id": "7bc505e5-f1a2-38c5-9af3-b5a76e7d247d",
        "contentType": "STORY",
        "title": "A Look At Viatris (VTRS) Valuation After Earnings Beat And 2026 Guidance Update",
        "description": "",
        "summary": "Viatris (VTRS) shares reacted to a busy update cycle after the company reported a fourth quarter revenue and adjusted earnings beat, along with fresh 2026 guidance, a cost saving plan, and refreshed capital return commitments. See our latest analysis for Viatris. Even after a 5.16% one day share price decline and a 4.57% seven day share price pullback around the earnings release and guidance, Viatris is still up 16.23% on a 30 day share price basis and 42.66% over 90 days. Its 1 year total...",
        "pubDate": "2026-02-27T09:14:19Z",
        "displayTime": "2026-02-27T09:14:19Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pVOKMAerbRsXv56pHka6Lw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EmyGBi4taxQExvvwka_9KQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/look-viatris-vtrs-valuation-earnings-091419452.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/look-viatris-vtrs-valuation-earnings-091419452.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VTRS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-27T12:02:45+00:00",
    "headline": "Viatris Inc. (VTRS) FDA Accepts sNDA for Presbyopia Treatment with October PDUFA Date",
    "summary": "Viatris Inc. (NASDAQ:VTRS) is one of the most undervalued stocks under $30 to buy. On February 25, Viatris announced that the FDA accepted its sNDA for MR-141, which is a phentolamine ophthalmic solution 0.75% intended to treat presbyopia. The FDA set a PDUFA goal date of October 17 this year, to complete its review. Presbyopia […]",
    "url": "https://finance.yahoo.com/news/viatris-inc-vtrs-fda-accepts-120245882.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "5c4024f4-e3e2-3992-a180-bc1c2abafede",
      "content": {
        "id": "5c4024f4-e3e2-3992-a180-bc1c2abafede",
        "contentType": "STORY",
        "title": "Viatris Inc. (VTRS) FDA Accepts sNDA for Presbyopia Treatment with October PDUFA Date",
        "description": "",
        "summary": "Viatris Inc. (NASDAQ:VTRS) is one of the most undervalued stocks under $30 to buy. On February 25, Viatris announced that the FDA accepted its sNDA for MR-141, which is a phentolamine ophthalmic solution 0.75% intended to treat presbyopia. The FDA set a PDUFA goal date of October 17 this year, to complete its review. Presbyopia […]",
        "pubDate": "2026-02-27T12:02:45Z",
        "displayTime": "2026-02-27T12:02:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/43deb06536953ffbb4aff65516944a46",
          "originalWidth": 750,
          "originalHeight": 500,
          "caption": "Viatris Inc. (VTRS) FDA Accepts sNDA for Presbyopia Treatment with October PDUFA Date",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ij3mfZSTHmlkxYV1UNwF6A--~B/aD01MDA7dz03NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/43deb06536953ffbb4aff65516944a46.cf.webp",
              "width": 750,
              "height": 500,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5GheayVE.H54Zy_d1E0WbA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/43deb06536953ffbb4aff65516944a46.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/viatris-inc-vtrs-fda-accepts-120245882.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/viatris-inc-vtrs-fda-accepts-120245882.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VTRS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]